deltatrials
Completed PHASE1 INTERVENTIONAL 1-arm NCT02534506

Study of Urelumab in Subjects With Advanced and/or Metastatic Malignant Tumors

A Phase 1 Study of the Safety, Tolerability, Pharmacokinetics and Immunoregulatory Activity of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Malignant Tumors

Sponsor: Bristol-Myers Squibb

Conditions Malignant Tumors
Interventions Nivolumab Urelumab
Updated 14 times since 2017 Last updated: May 14, 2020 Started: Nov 6, 2015 Primary completion: Nov 11, 2016 Completion: Nov 11, 2016
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Malignant Tumors, this trial is completed. The trial is conducted by Bristol-Myers Squibb and has accumulated 14 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Apr 2017 · 59 days · monthly snapshot~Apr 2017 – ~May 2017 · 30 days · monthly snapshot~May 2017 – ~Jun 2018 · 13 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Nov 2018 · 3 months · monthly snapshot~Nov 2018 – ~Feb 2019 · 3 months · monthly snapshot~Feb 2019 – ~Sep 2019 · 7 months · monthly snapshot~Sep 2019 – ~Jun 2020 · 9 months · monthly snapshot~Jun 2020 – ~Jan 2021 · 7 months · monthly snapshot~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE1

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  5. Jun 2020 — Jan 2021 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

▶ Show 9 earlier versions

  1. Sep 2019 — Jun 2020 [monthly]

    Active Not Recruiting PHASE1

  2. Feb 2019 — Sep 2019 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  3. Nov 2018 — Feb 2019 [monthly]

    Recruiting PHASE1

  4. Aug 2018 — Nov 2018 [monthly]

    Recruiting PHASE1

  5. Jun 2018 — Aug 2018 [monthly]

    Recruiting PHASE1

  6. May 2017 — Jun 2018 [monthly]

    Recruiting PHASE1

  7. Apr 2017 — May 2017 [monthly]

    Recruiting PHASE1

    Status: Active Not Recruiting → Recruiting

  8. Feb 2017 — Apr 2017 [monthly]

    Active Not Recruiting PHASE1

  9. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE1

    First recorded

Nov 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bristol-Myers Squibb
  • Ono Pharmaceutical Co. Ltd
Data source: Bristol-Myers Squibb

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations